in the nucleus, while class II HDACs (4, 5, 6, 7, 9, and 10) are seen in both the nucleus and the cytoplasm. 3, 4 The class IV family consists of HDAC11, which shares features of both class I and class II enzymes. 4 Several classes of HDACi have been identified (see Table 1 ):
• short-chain fatty acids, such as phenylbutyrates; 7 • hydroxamic acids, including trichostatin A (TSA); 8 • vorinostat (suberoylanilide hydroxamic acid (SAHA)), 9 oxamflatin, belinostat (PXD101), LAQ824, and LBH589;
• cyclic tetrapeptides containing a 2-amino-8-oxo-9, 10-epoxy-decanoyl Thirteen of these patients were treated with oral vorinostat 400mg daily (Group 1). The other participants received different dosing regimens of vorinostat. For the 13 patients in Group 1, the overall response rate was 31%.
In Group 1, the most common drug-related adverse events were fatigue, thrombocytopenia, nausea, and diarrhea, with ≥grade 3 or 4 adverse events including thrombocytopenia in one patient, anemia in one patient, and dehydration in one patient, as well as some ≥grade 3 chemistry abnormalities. observed, but four patients (29%) had stable disease (SD) for a median of ≥8.7 months (four to 13 months). Toxicities included fatigue, diarrhea, nausea, mucositis, and lymphopenia. 15 A similar treatment dose and schedule were used in a study of 68 patients with recurrent glioblastoma multiforme (GBM). The primary efficacy end-point of this study was a sixmonth progression-free survival rate (PFS6 rate) of 25%. At the time of the planned interim analysis, which included the first 22 patients, five patients were progression-free at six months for a PFS6 rate of 23%, which, according to the authors, met the trial's prospectively defined primary efficacy end-point. The most common adverse events included fatigue, diarrhea, dehydration, and thrombocytopenia. 16 Two other trials examined the 400mg daily dose of oral vorinostat. Early results have been reported for a study sponsored by the Prostate Cancer Clinical Trials Consortium (PCCTC). Twenty-three patients had been enrolled, but only nine were evaluated for response at the time of the report. Of these nine patients, three had SD. 17 In a phase II study of vorinostat in non-smallcell lung cancer (NSCLC) patients with relapsed disease who had progressed through ≤1 prior cytotoxic therapy, data have been presented on the first 14 patients treated. In 12 patients evaluable for response, no ORs occurred, but seven patients (58%) had SD. Median overall survival (OS) was 6.5 months, with an estimated six-month OS rate of 50% (standard error (SE) 16%). In addition to the expected toxicities, four of 14 patients evaluable for safety experienced adverse vascular events, including two patients with pulmonary embolism and one patient with a fatal cardiovascular accident (CVA). 
Phase II data on romidepsin have been reported for patients with chemotherapy-naïve metastatic hormone-refractory prostate cancer A phase II study of romidepsin in patients with metastatic neuroendocrine tumors was terminated prematurely due to the occurrence of several serious cardiac adverse events in the 15 patients treated. These included a sudden death attributed to possible ventricular arrhythmia, asymptomatic grade 2 ventricular tachycardia in two patients, and prolonged QTc in three patients. 22 As noted above, such significant cardiac toxicity has not been noted in other clinical trials of romidepsin in treatment of solid tumors.
Other Histone Deacetylase Inhibitors
CI-994 is an oral benzamide HDACi that had low response rates when used as a single agent in two phase II studies conducted in the 1990s. weeks. The most frequently reported adverse events were nausea, diarrhea, and hypophosphatemia. 25 Pivaloyloxymethyl butyrate (Pivanex, AN-9) is a prodrug of the shortchain fatty acid butyrate. In a multicenter phase II trial, AN-9 was administered at 2.34g/m 2 as a six-hour IV infusion daily for three days every 21 days to 47 patients with refractory NSCLC. Three patients (6.4%) had a PR, while 14 (30%) had SD lasting 12 weeks: median OS was 6.2 months, with one-year OS 26%. The most common toxicities were fatigue, nausea, and dysgeusia. 26 A few other active phase II trials assessing HDACi as single-agent therapy are examining belinostat (PXD101) in unresectable hepatocellular carcinoma, 27 oral LBH589 in refractory CTCL, and valproic acid in advanced thyroid cancer.
Rationale for Combination Therapy
While in many trials response rates in solid tumors have not been impressive, a significant amount of stable disease has been noted, leading to interest in the assessment of HDACi in combination with other There is pre-clinical evidence to support this. For example, vorinostat enhanced radiation-induced apoptosis and reduced tumor survival after radiation exposure in human prostate and glioma cell lines. 33 Several
HDACi were shown to enhance sensitivity to ionizing radiation in two human squamous carcinoma cell lines previously characterized as intrinsically resistant to radiation, with some evidence to suggest a mechanism of action involving cell cycle arrest in the G1 phase and inhibition of DNA synthesis. 34 In a xenograft model using a human prostate tumor cell line, the combination of MS-275 with radiation resulted in greater than additive inhibition of tumor growth compared with MS-275 or radiation alone. shown to greatly enhance apoptosis induced by romidepsin or TSA in several human lung cancer cell lines. 40 Such combinations are already being examined in clinical trials for solid tumors (see Table 3 ) and hematological malignancies, and data have been reported on a clinical trial using decitabine in combination with the HDACi sodium phenylbutyrate (PB) in patients with acute myeloid leukemia and those with myelodysplastic syndrome. 
